Mural Oncology
MURA
MURA was delisted on the 4th of December, 2025.
123 hedge funds and large institutions have $79.1M invested in Mural Oncology in 2023 Q4 according to their latest regulatory filings, with 123 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
80.03% more ownership
Funds ownership: 0% → 80.03% (+80%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$7.98M |
| 2 |
AC
Armistice Capital
New York
|
+$6.67M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.13M |
| 4 |
BlackRock
New York
|
+$4.72M |
| 5 |
AFA
Alta Fundamental Advisers
New York
|
+$2.41M |
Top Sellers
MURA Hedge Fund Activity: Q4 2023 in Review
123 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Mural Oncology (MURA) for Q4 2023, worth a combined $79.1M.
Buyers outnumbered sellers: 123 funds opened new MURA positions and 0 closed out — a net gain of 123 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $7.98M.
- 123 institutional investors held Mural Oncology (MURA) as of Q4 2023, up from 0 in Q3 2023.
- Funds reported $79.1M of Mural Oncology stock for Q4 2023.
- 123 funds opened new Mural Oncology positions in Q4 2023 and 0 closed out, a net change of +123 holders.
- The largest Mural Oncology buyer in Q4 2023 was Westfield Capital Management, an estimated $7.98M added.
Based on aggregated 13F filings for Q4 2023.